New Report Begins a New Era of Stem Cell Science and Medicine: Stem Cell Biotechnology Company Asymmetrex Tells How It Counts Therapeutic Tissue Stem Cells

In an August 28 special issue of the peer-reviewed online journal OBM Transplantation, stem cell biotechnology company Asymmetrex has now published a report describing how its technology for determining the specific dosage of therapeutic tissue stem cells works. The new technology is poised to revolutionize stem cell science and stem cell medicine by giving the

Learn How to Get a Tissue Stem Cell Count Easily

Asymmetrex’s Plan for Free Stem Cell Counting Is The Feature Story by Superb Crew News

This week, Massachusetts stem cell biotechnology company Asymmetrex was the feature news story by online business and technology news platform Superb Crew. The attraction for the choice of Asymmetrex is the company’s recent announcement of its plan to begin offering free tissue stem cell counting to the stem cell research, stem cell medicine, and pharmaceutical

Asymmetrex Announces Plans to Provide Free Tissue Stem Cell Counting

Today, June 16, Massachusetts stem cell biotechnology company Asymmetrex announces that it will begin offering free tissue stem cell counting on its company website. Scheduled for opening July 5, Independence Day weekend in the U.S., the company’s counting site will give academic scientists, stem cell medicine physicians, tissue stem cell suppliers, and drug companies a

Asymmetrex Director Sherley Addresses the Clinical Trial Supply Industry About the Benefits of Stem Cell Counting

May 12, 2020   In Arena International’s Clinical Trial Supply 2020 Virtual Experience online conference, Asymmetrex Director James Sherley discussed unique challenges in the supply chain of therapies for stem cell transplantation medicine, gene therapy, and gene-editing therapy that can be readily addressed by greater use of tissue stem cell counting technologies like those developed

medRxiv Publishes Asymmetrex Director’s Analysis of a Misread on COVID-19 Spread

Based on interrogation of public coronavirus data, Asymmetrex Director Sherley reports suspicion of a misread on COVID-19 spread In a preprint posted on medRxiv, Asymmetrex Director James Sherley reports the discovery of surprising relationships between how many positive coronavirus tests are found and how many tests were given.  Everyone recognizes that if no tests were

SuperbCrew Interviews Asymmetrex CEO James L. Sherley

SuperbCrew, a business news website dedicated to covering innovative companies in the tech and business fields, recently interviewed Asymmetrex CEO James L. Sherley. Dr. Sherley discusses Asymmetrex’s background, his personal background, and the newly developed algorithms for rapid low cost counting of therapeutic tissue stem cells. “Together AlphaSTAR and Asymmetrex solve the 6 decades unsolved

Asymmetrex Announces New Algorithms for Rapid Low Cost Counting of Therapeutic Tissue Stem Cells

Today, at the 6th Annual Perinatal Stem Cell Society Congress in Salt Lake City, Utah, Massachusetts stem cell biotechnology company Asymmetrex will announce its newest advance in technologies for specific counting of tissue stem cells. The company will report the use of its AlphaSTEM Test™ technology to discover the first mathematical algorithms for rapidly calculating

Asymmetrex’s Podcast Series Featured on RegMedNet

RegMedNet highlighted Asymmetrex and its Counting Stem Cells podcast from James Sherley, founder and director of Asymmetrex. The Counting Stem Cells podcast has six episodes outlining current usage of stem cells, the current counting problem, why it matters, the Asymmetrex solution, and a vision for the future. “We cannot continue to work in the field

Asymmetrex Talks with Tech Company News About Introducing Tissue Stem Cell Counting to the Advanced Regenerative Manufacturing Institute (ARMI)

Online news platform Tech Company News caught up with Asymmetrex Director James Sherley to ask him about his expectations for Asymmetrex’s new membership in ARMI. “Working with our partner AlphaSTAR Corporation, Asymmetrex has solved the first problem. We now offer the first ever technology for specific and accurate counting of any human tissue stem cell type, including